The business was sold for $85 million, and the expenses are expected to repay existing debt. The sale aims to help the company “enhance our liquidity and enable a greater focus on execution,” interim CEO Tony Bihl said in the release.
The move comes just over a month after Bioventus’ former CEO, Ken Reali, resigned.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
